US Financial Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

US Financial Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-14	Closed	-$2K	–	221
2016 Q1	$2K	Hold	14	–	–	﹤0.01%	325
2015 Q4	$2K	Hold	14	–	–	﹤0.01%	461
2015 Q3	$2K	Hold	14	–	–	﹤0.01%	399
2015 Q2	$2K	Buy	+14	New	+$2.51K	﹤0.01%	379

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

US Financial Advisors's JAZZ Position: Q2 2016 in Review

US Financial Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2016, closing a stake of 14 shares — an estimated $2K sold.

US Financial Advisors first reported a position in JAZZ in Q2 2015 and held it in 4 quarters. The position peaked at $2K in Q1 2016. 366 funds tracked by Wall St. Rank hold JAZZ as of Q2 2016.

US Financial Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
US Financial Advisors sold 14 Jazz Pharmaceuticals shares in Q2 2016, an estimated $2K.
US Financial Advisors first reported a position in Jazz Pharmaceuticals in Q2 2015 and held it in 4 quarters.
US Financial Advisors's Jazz Pharmaceuticals position peaked at $2K in Q1 2016.
366 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2016.

Based on US Financial Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.